Spectroscopic study of L-DOPA and dopamine binding on novel gold nanoparticles towards more efficient drug-delivery system for Parkinson’s disease

Kalčec, Nikolina; Peranić, Nikolina; Barbir, Rinea; Smith, Trevor A.; Sani, Marc‐Antoine; Frkanec, Ruža; Separovic, Frances; Vrček, Ivana Vinković

doi:10.1016/j.saa.2021.120707

Cited by 11 publications

(8 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…59 Such bonding between biomolecules and other types of NPs is reported in the literature. 49,60 Hydrophobic interactions were not a factor in the binding of L-DOPA and dopamine with SeNPs, which is in accordance with previously published results for AuNPs. 60 ΔG 0 values, obtained according to eq 6, showed negative values (Table 4) which indicate that the binding processes occurred spontaneously.…”

Section: Steady-state and Time-resolved Fluorescence Measurementssupporting

confidence: 92%

“…49,60 Hydrophobic interactions were not a factor in the binding of L-DOPA and dopamine with SeNPs, which is in accordance with previously published results for AuNPs. 60 ΔG 0 values, obtained according to eq 6, showed negative values (Table 4) which indicate that the binding processes occurred spontaneously. 61 Additionally, it was crucial to assess the impact of proteins existing within biological media on the binding process.…”

Section: Steady-state and Time-resolved Fluorescence Measurementssupporting

confidence: 92%

“…However, there were differences in the percentage of reduction depending on the functionalizing agents. In our previous paper on AuNPs, the impact of bovine serum protein (BSA) was investigated, and the lowest reduction in K values was observed for the NPs that had the strongest binding affinity to l -DOPA and dopamine . Interestingly, the results obtained here showed the opposite effect.…”

Section: Resultsmentioning

confidence: 64%

See 2 more Smart Citations

Selenium Nanoparticles as Potential Drug-Delivery Systems for the Treatment of Parkinson’s Disease

Kalčec,

Peranić,

Mamić

et al. 2023

ACS Appl. Nano Mater.

Self Cite

View full text Add to dashboard Cite

The development of efficient drug formulations for Parkinson's disease (PD) treatment is challenged by achieving pharmacokinetic profiles, reduced side effects, and better permeability through the blood−brain barrier (BBB). As nanoparticles may facilitate the delivery of drugs in the brain due to their high-loading capacity and ability to cross biological barriers, we designed two different types of selenium nanoparticles (SeNPs) that may increase the transport of drugs across the BBB and may act as antioxidants at the site of action. The SeNPs were functionalized with polyvinylpyrrolidone (PVP) and polysorbate 20 (Tween) and characterized in terms of their size, size distribution, shape, surface charge, and colloidal stability in relevant biological media. Their drug-loading capacity was tested using dopamine and L-DOPA as therapeutically active agents for PD. Thermodynamic analysis revealed that binding processes occurred spontaneously through hydrogen bond/van der Waals interactions or electrostatic interactions. The strongest interaction was observed between PVP-SeNPs and L-DOPA or dopamine, which was characterized by a binding constant several orders of magnitude higher than for Tween-SeNPs. However, the addition of human transferrin as a model plasma protein significantly reduced this difference, which indicates the crucial role of protein corona formation in the design of drug nanodelivery systems. In vitro evaluation by cell-free and cellular transwell models showed efficient internalization of SeNP-loaded L-DOPA/dopamine by human endothelial brain cells, while facilitated BBB permeability for L-DOPA, and dopamine was achieved using PVP-SeNPs. Overall, the high potential of SeNPs as drug-delivery vehicles in PD treatment was demonstrated.

show abstract

Section: Steady-state and Time-resolved Fluorescence Measurementssupporting

confidence: 92%

Section: Steady-state and Time-resolved Fluorescence Measurementssupporting

confidence: 92%

Section: Resultsmentioning

confidence: 64%

See 1 more Smart Citation

Selenium Nanoparticles as Potential Drug-Delivery Systems for the Treatment of Parkinson’s Disease

Kalčec,

Peranić,

Mamić

et al. 2023

ACS Appl. Nano Mater.

Self Cite

View full text Add to dashboard Cite

show abstract

“…The results showed that the lifetime of the samples in the presence of LD and DA was lower than in the absence of LD and DA, which can be attributed to electron transfer which conrms the dynamic quenching mechanism. 88,94 Dynamic quenching generally occurs through electron transfer. 95 Luminescence intensity is determined by electron-hole pair recombination, a well-known mechanism that depends intensely on surface states.…”

Section: Papermentioning

confidence: 99%

A bacterial cellulose-based LiSrVO₄:Eu³⁺ nanosensor platform for smartphone sensing of levodopa and dopamine: point-of-care diagnosis of Parkinson's disease

Mahdavi¹,

Emadi²,

Nabavi³

2023

Nanoscale Adv.

View full text Add to dashboard Cite

show abstract

“…Rout et al (2020) [ 175 ] studied the binding interaction of DA with AuNPs using steady-state and time-resolved fluorescence spectroscopic tools. Similarly, Kalčec et al (2022) [ 176 ] studied the DA loading efficiency for peptidoglycan monomer-coated AuNPs by fluorescence and UV-Vis measurements. The results of both groups suggest the possibility of using these nanostructures as drug delivery models in DA-related diseases, whose functionalization could probably fit multiple functions, i.e., efficient drug-loading, BBB-penetrating, and CNS-targeting system DA.…”

Section: Controlled Drug Delivery On Parkinson’s Diseasementioning

confidence: 99%

Nanomedicine in the Face of Parkinson’s Disease: From Drug Delivery Systems to Nanozymes

Padilla-Godínez

Ruiz-Ortega

Guerra-Crespo

2022

Cells

View full text Add to dashboard Cite

The complexity and overall burden of Parkinson’s disease (PD) require new pharmacological approaches to counteract the symptomatology while reducing the progressive neurodegeneration of affected dopaminergic neurons. Since the pathophysiological signature of PD is characterized by the loss of physiological levels of dopamine (DA) and the misfolding and aggregation of the alpha-synuclein (α-syn) protein, new proposals seek to restore the lost DA and inhibit the progressive damage derived from pathological α-syn and its impact in terms of oxidative stress. In this line, nanomedicine (the medical application of nanotechnology) has achieved significant advances in the development of nanocarriers capable of transporting and delivering basal state DA in a controlled manner in the tissues of interest, as well as highly selective catalytic nanostructures with enzyme-like properties for the elimination of reactive oxygen species (responsible for oxidative stress) and the proteolysis of misfolded proteins. Although some of these proposals remain in their early stages, the deepening of our knowledge concerning the pathological processes of PD and the advances in nanomedicine could endow for the development of potential treatments for this still incurable condition. Therefore, in this paper, we offer: (i) a brief summary of the most recent findings concerning the physiology of motor regulation and (ii) the molecular neuropathological processes associated with PD, together with (iii) a recapitulation of the current progress in controlled DA release by nanocarriers and (iv) the design of nanozymes, catalytic nanostructures with oxidoreductase-, chaperon, and protease-like properties. Finally, we conclude by describing the prospects and knowledge gaps to overcome and consider as research into nanotherapies for PD continues, especially when clinical translations take place.

show abstract

Spectroscopic study of L-DOPA and dopamine binding on novel gold nanoparticles towards more efficient drug-delivery system for Parkinson’s disease

Cited by 11 publications

References 64 publications

Selenium Nanoparticles as Potential Drug-Delivery Systems for the Treatment of Parkinson’s Disease

Selenium Nanoparticles as Potential Drug-Delivery Systems for the Treatment of Parkinson’s Disease

A bacterial cellulose-based LiSrVO₄:Eu³⁺ nanosensor platform for smartphone sensing of levodopa and dopamine: point-of-care diagnosis of Parkinson's disease

Nanomedicine in the Face of Parkinson’s Disease: From Drug Delivery Systems to Nanozymes

Contact Info

Product

Resources

About

Spectroscopic study of L-DOPA and dopamine binding on novel gold nanoparticles towards more efficient drug-delivery system for Parkinson’s disease

Cited by 11 publications

References 64 publications

Selenium Nanoparticles as Potential Drug-Delivery Systems for the Treatment of Parkinson’s Disease

Selenium Nanoparticles as Potential Drug-Delivery Systems for the Treatment of Parkinson’s Disease

A bacterial cellulose-based LiSrVO4:Eu3+ nanosensor platform for smartphone sensing of levodopa and dopamine: point-of-care diagnosis of Parkinson's disease

Nanomedicine in the Face of Parkinson’s Disease: From Drug Delivery Systems to Nanozymes

Contact Info

Product

Resources

About

A bacterial cellulose-based LiSrVO₄:Eu³⁺ nanosensor platform for smartphone sensing of levodopa and dopamine: point-of-care diagnosis of Parkinson's disease